Summary: Clozapine, an antipsychotic medication, can induce or worsen obsessive-compulsive symptoms (OCS) in some patients. Adding aripiprazole, with or without reducing the clozapine dose, appears to be an effective management option in many cases.
Source: Journal of Psychotherapy and Psychosomatics
A systematic review published in Psychotherapy and Psychosomatics examines obsessive and compulsive symptoms associated with clozapine treatment and summarizes strategies for managing these adverse effects.
Obsessive-compulsive symptoms (OCS) are not rare among patients treated with clozapine. These symptoms are thought to arise in part from clozapine’s strong anti-serotonergic activity. To clarify how often these problems occur, which patients are most at risk, and which treatments help, researchers conducted a systematic review of published case reports and case series describing clozapine-associated OCS.
Search and selection
The authors searched MEDLINE, Embase, and PsycINFO without restrictions on language or publication year, capturing reports up to July 11, 2019. Fifty-seven studies met inclusion criteria, yielding a total of 107 cases in which clozapine either induced new OCS (de novo, n = 75) or exacerbated preexisting OCS (n = 32).
Clinical characteristics
Reported OCS varied in timing and intensity. Symptoms emerged across a wide range of clozapine doses (100–900 mg/day) and after varied treatment durations, with a median onset at about six months (interquartile range two to 24 months). Many cases presented with moderate to severe symptoms. Greater severity correlated with several factors: the presence of prior OCS, poorer insight into the obsessive-compulsive symptoms, and active psychosis at the time the OCS appeared.
Management approaches and outcomes
Treatment strategies described in the reviewed cases commonly included the addition of antidepressant medications—primarily selective serotonin reuptake inhibitors (SSRIs) or clomipramine—as well as the introduction of aripiprazole. Often clinicians also attempted a reduction in clozapine dose when feasible. Across the reported cases, the overall response rate to antidepressant treatment was approximately 49% (29 of 59 cases). Factors associated with a better antidepressant response included younger patient age, a shorter overall duration of the underlying psychiatric illness, shorter duration of clozapine treatment prior to OCS onset, better insight into the obsessive-compulsive symptoms, and the presence of so-called taboo thoughts.
For patients who did not respond to antidepressants, lowering the clozapine dose proved helpful in a number of instances. In about half of those cases where dose reduction was applied, clinicians also added aripiprazole concurrently. The review highlights aripiprazole—either as an adjunct or in combination with a clozapine dose reduction—as a promising alternative or complement to standard antidepressant strategies for managing clozapine-associated OCS.
Implications for clinicians
These findings emphasize that clozapine can precipitate clinically significant obsessive-compulsive symptoms, sometimes severe enough to impair functioning or complicate psychiatric care. Clinicians prescribing clozapine should routinely monitor patients for emerging OCS, assess insight and symptom severity, and consider patient history of obsessive-compulsive disorder when evaluating risk. When OCS develop, treatment options include introducing an SSRI or clomipramine, reducing the clozapine dose when clinically acceptable, and/or adding aripiprazole. Treatment choice should be individualized, balancing the need to maintain antipsychotic efficacy against the severity of OCS and the risks of psychotic relapse.
About this neuroscience research article
Source:
Journal of Psychotherapy and Psychosomatics
Media Contacts:
Press Office – Journal of Psychotherapy and Psychosomatics
Image Source:
The image is in the public domain.
Original research
Title: “Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases” by David D. Kim et al.
Published in Psychotherapy and Psychosomatics. DOI: 10.1159/000505876
Abstract (summary)
Background: Obsessive-compulsive symptoms can arise during clozapine treatment, likely related to its anti-serotonergic effects. This review aimed to synthesize reported cases to better understand presentation and management.
Methods: A comprehensive search of MEDLINE, Embase, and PsycINFO identified case reports and case series of clozapine-associated OCS up to July 11, 2019.
Results: Fifty-seven studies comprising 107 cases (75 de novo, 32 exacerbated) showed OCS onset across a broad dose range and typically within months of treatment. Higher severity related to prior OCS, poor insight, and concurrent psychosis. Common management strategies were antidepressants (SSRIs or clomipramine), clozapine dose reduction, and addition of aripiprazole. Antidepressant response was seen in about half of treated cases; dose reduction and aripiprazole addition helped many non-responders.
Conclusions: Clozapine can provoke significant obsessive-compulsive symptoms. Adding aripiprazole, with or without clozapine dose reduction, offers a viable alternative or adjunct to antidepressants for these cases. Clinicians should remain vigilant for these adverse effects and tailor management to each patient’s clinical context.
Feel free to share this neuroscience news.